1,7-Dioxaspiro(5.5)undecane is a bicyclic ether that has been studied for its potential as a building block in organic synthesis. It has been synthesized through a variety of methods, including the reaction of 1,5-pentanediol with diethyl carbonate. The compound's unique structure and reactivity have made it a target for investigations into its use as a precursor to other cyclic compounds, such as spiroketals and spirolactones, which are found in many natural products and pharmaceuticals. It is particularly notable for its ability to undergo ring-opening reactions, which can be utilized in the construction of complex molecules.'
```
1,7-dioxaspiro(5.5)undecane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 67437 |
| CHEMBL ID | 2135489 |
| CHEBI ID | 195752 |
| SCHEMBL ID | 1720520 |
| MeSH ID | M0270443 |
| Synonym |
|---|
| 1,7-dioxaspiro(5.5)undecane |
| LMPK09000013 |
| LMPK09000012 |
| (r)-1,7-dioxaspiro[5.5]undecane |
| inchi=1/c9h16o2/c1-3-7-10-9(5-1)6-2-4-8-11-9/h1-8h |
| 1,7-dioxaspiro[5.5]undecane |
| NCGC00164386-01 |
| 1,7-dioxaspiro[5.5]undecane, >=97% |
| (s)-1,7-dioxaspiro[5.5]undecane |
| CHEBI:195752 |
| 180-84-7 |
| NCGC00164386-02 |
| 1,7-dioxaspiro[5.5]undecan |
| olean |
| einecs 205-870-7 |
| unii-khi3qeq4zj |
| khi3qeq4zj , |
| eco-trap |
| dtxsid2040735 , |
| tox21_300659 |
| dtxcid0020735 |
| cas-180-84-7 |
| NCGC00254567-01 |
| FT-0607027 |
| AKOS025294760 |
| SCHEMBL1720520 |
| CHEMBL2135489 |
| dioxaspiro-5,5-undecane, 1,7- |
| 1,7-dioxaspiro[5,5]undecane |
| mfcd00011578 |
| 1,7-dioxaspiro[5.5]undecane, 98% |
| AS-59233 |
| J-011547 |
| Q55620476 |
| Q55620521 |
| 1,7-dioxaspiro[5.5]undecane; olean |
| Q804105 |
| CS-0333807 |
| 1,7-dioxaspiro[5.5]undecane 100 microg/ml in acetonitrile |
| ?1,7-dioxaspiro[5.5]undecane |
| Class | Description |
|---|---|
| ketal | An acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.4753 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
| AR protein | Homo sapiens (human) | Potency | 15.3553 | 0.0002 | 21.2231 | 8,912.5098 | AID743042 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.0032 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||